Bluejay Diagnostics, Inc. Common Stock (BJDX) Stock Price
BJDXStock
$0.74−93.67%52W
Market Cap$3.33M
P/E—
PEG Ratio—
Div yield—
Beta0.94
BJDX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-69.88%
Price vs S&P 500 (4W)-17.04%
VGM Score8.20
BJDX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q4 2023 | -$1360.00 | -$2848.00 | -109.41%(-$1488.00) | |
| Q3 2023 | -$1344.00 | -$3328.00 | -147.62%(-$1984.00) | |
| Q2 2023 | -$2240.00 | -$4400.00 | -96.43%(-$2160.00) |
BJDX Analyst Recommendations
Apr 2024
May 2024
Jun 2024
Jul 2024
2.17
2.17
2.17
2.17
Industry Peers — Surgical & Medical Instruments(142)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
BJDXBluejay Diagnostics, Inc. Common Stock | — | F | F | — | — | — | — | $0.74 |
| SYKStryker Corporation | C | B | C | 4.4x | 11.8% | 65.3% | 21.3% | $294.66 |
| MMM3M Company | C | D | B | 3.4x | -5.0% | 39.4% | 18.4% | $164.75 |
| BSXBoston Scientific Corp. | C | B | C | 3.1x | 15.2% | 69.5% | 19.8% | $44.39 |
| BDXBecton, Dickinson and Co. | B | D | A | 2.5x | 6.3% | 46.7% | 9.6% | $191.75 |
| MDLNMedline Inc. Class A common stock | C | D | C | 1.6x | — | 26.2% | 6.0% | $35.96 |
| RMDResMed Inc. | C | C | B | 5.9x | 12.1% | 61.1% | 33.4% | $238.97 |
| DXCMDexCom, Inc. | C | B | B | 6.5x | 19.3% | 64.3% | 22.9% | $86.04 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | 8.5x | 7.4% | 36.8% | 20.4% | $384.02 |
| SOLVSolventum Corporation | C | C | B | 1.8x | — | 54.8% | 23.9% | $85.81 |
| BAXBaxter International Inc. | B | D | B | 1.1x | -0.8% | 30.7% | -2.3% | $25.28 |
About Bluejay Diagnostics, Inc. Common Stock
Bluejay Diagnostics develops the Symphony System, a rapid, cost-effective near-patient testing platform for sepsis diagnosis and monitoring. Its first product, an IL-6 sepsis test, delivers results in approximately 20 minutes, enabling faster clinical decision-making and improved patient outcomes. The platform addresses a critical clinical need in acute care settings where rapid sepsis diagnosis is essential for treatment efficacy.